Home  >  News
Biotechnology + Font Resize -

GSK' shingles vaccine Shingrix receives Canadian approval

London, UK
Monday, October 16, 2017, 16:00 Hrs  [IST]

GlaxoSmithKline has announced that Shingrix has been approved in Canada for the prevention of shingles (herpes zoster) in people aged 50 years or older Shingrix is a non-live, recombinant subunit adjuvanted vaccine given intramuscularly in two doses.

Shingles is caused by reactivation of the varicella zoster virus, the same virus that causes chickenpox. A person’s risk for shingles increases sharply after 50 years of age. Nearly all adults over 50 have the shingles virus dormant in their nervous system, waiting to reactivate with advancing age. Up to one in three Canadians will develop shingles in their lifetime.

“One of the biggest challenges in vaccine research is to create vaccines that are effective in older adults who are at greater risk for certain diseases, like shingles. As we age, our immune system loses the ability to mount a strong and effective response to infection. Shingrix was developed specifically to overcome the age-related decline in immunity against the varicella zoster virus,” said Dr Thomas Breuer, senior vice president and chief medical officer of GSK Vaccines.

Shingrix is the first shingles vaccine to combine a non-live antigen, to trigger a targeted immune response, with a specifically designed adjuvant to generate a strong and sustained immune response.

Regulatory reviews of Shingrix are underway in the US, EU, Australia and Japan.

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
duphat_150x60
IPJPI18_150x60en_2018
PHARMACONNECT_2018
 
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |